What does vitamin D deficiency mean? Definitions, thresholds and what really helps

⏱ 9 min read

A familiar pattern prompts most vitamin D questions: winter months or long hours indoors, nagging tiredness, more frequent colds, and a routine blood test showing a low level. A 2026 analysis by Hou and colleagues highlighted a related concern: high-dose vitamin D for fall prevention needs clinical nuance and careful safety monitoring, not one-size-fits-all dosing (Hou et al., 2026). Against that backdrop, this guide sets out what deficiency means, how common it is in Europe, how to test and interpret results properly, and which measures correct a low level safely.

Vitamin D deficiency is defined by a low blood concentration of 25-hydroxyvitamin D [25(OH)D], the circulating form used to assess status. Bone health outcomes anchor most definitions: in the UK, the Scientific Advisory Committee on Nutrition (SACN) considers <25 nmol/L a level associated with increased risk of poor musculoskeletal health (SACN, 2016). Many European researchers and the Endocrine Society consider <50 nmol/L (20 ng/mL) as deficient for wider risk assessment (Holick et al., 2011), while some define insufficiency between 50-75 nmol/L.

• Assessment marker: 25(OH)D in serum or plasma reflects vitamin D supply from sun, diet, and supplements.
• Common cut-offs: <25 nmol/L (UK SACN risk threshold); <50 nmol/L (widely used deficiency threshold).
• Bone focus: thresholds are based mainly on rickets/osteomalacia risk and calcium–bone metabolism.
• EU intake context: EFSA sets an adequate intake of 15 µg/day for adults; this is not a treatment dose.

The practical takeaway is simple: use the same threshold throughout an assessment, interpret it with the person’s symptoms and risks, and plan correction based on the baseline value rather than a generic dose.

How common is vitamin D deficiency in Europe?

European surveillance consistently shows a seasonal, geographical, and demographic pattern: deficiency is more frequent in winter, at higher latitudes, and in groups with less sun exposure or darker skin. The ODIN project pooled data from several European populations and reported substantial proportions with 25(OH)D <50 nmol/L, especially in northern regions and winter months (Cashman et al., 2016). A later European review confirmed that low status remains prevalent despite increased awareness (Hilger et al., 2014; Spiro & Buttriss, 2014).

• Latitude and season: synthesis in skin is minimal in winter above roughly 35-40°N; many EU countries lie further north.
• Skin pigmentation and clothing: melanin reduces cutaneous vitamin D production; full-coverage clothing blocks UVB.
• Indoor living and urbanisation: less midday outdoor time reduces UVB exposure even in sunny climates.
• Ageing: older skin synthesises vitamin D less effectively.

Numbers vary by country and method, but the pattern is clear enough for public-health guidance: winter and higher-latitude living sharply increase the risk of low status. Local fortification policies and supplement habits partly mitigate this.

Causes and risk factors: from sun exposure to malabsorption

Most deficiencies reflect insufficient UVB exposure combined with limited dietary supply. Additional contributors include conditions or drugs that impair absorption or metabolism. Understanding these drivers guides both prevention and correction.

• Limited UVB: high latitude winters, indoor work, sunscreen and clothing (all appropriate for skin protection) reduce cutaneous synthesis.
• Low intake: few foods naturally contain vitamin D; intake depends on oily fish, eggs, and fortification.
• Malabsorption: coeliac disease, inflammatory bowel disease, pancreatic insufficiency, or bariatric surgery can reduce absorption.
• Hepatic/renal issues and medications: liver or kidney disease and some anticonvulsants/glucocorticoids affect metabolism.

Context matters: the same dose can produce different 25(OH)D responses depending on body weight, baseline level, and absorption. Reviewing these factors avoids under- or over-correction.

Symptoms and consequences: from tiredness to bone disease

Vitamin D deficiency can be “silent”. When symptoms occur, they are often non-specific but may relate to musculoskeletal function. Severe, prolonged deficiency causes rickets in children and osteomalacia in adults; low status also contributes to osteoporosis risk through impaired calcium handling.

• Commonly reported: tiredness, muscle weakness or aches, low mood, and more frequent winter infections (non-specific).
• Musculoskeletal signs: bone pain, proximal muscle weakness, difficulty rising from a chair (osteomalacia).
• Skeletal outcomes: rickets/osteomalacia are established risks of sustained, severe deficiency.
• Falls and function: effects on muscle may influence fall risk; dosing strategy is crucial (Hou et al., 2026).

Because these complaints are non-specific, testing confirms whether vitamin D is a likely contributor and helps prioritise bone-protective measures where appropriate.

Getting the diagnosis right: 25(OH)D testing, units, and targets

A 25(OH)D blood test is the standard status measure. Laboratories report in nmol/L or ng/mL; multiply ng/mL by 2.5 to convert to nmol/L. Interpretation must use consistent thresholds and consider season, latitude, and risk factors.

• Test type: 25(OH)D; avoid confusing with 1,25(OH)₂D (not a status marker).
• Units: 1 ng/mL = 2.5 nmol/L; use one system consistently.
• Timing: retest after a defined correction period to confirm response.
• Targets: set in line with the definition used (e.g., ≥50 nmol/L), then personalise by risk and clinical context.

In practice, the pattern over time is more informative than a single result. Retesting demonstrates whether a chosen strategy is working and helps avoid overcorrection.

Correcting a deficiency: intake, dosing, and duration

Correction plans depend on baseline level, body weight, malabsorption risk, and adherence. Several randomised trials and clinical protocols use daily or weekly cholecalciferol with retesting after 8-12 weeks. Hou et al. (2026) emphasise caution with high-dose boluses in older adults when fall risk is a concern, supporting steady, monitored dosing rather than indiscriminate megadoses.

• Daily or weekly cholecalciferol: steady regimens raise 25(OH)D predictably; choose a schedule that fits adherence.
• Duration: retest typically after 8-12 weeks to assess response and adjust.
• Safety context: EFSA names 100 µg/day (4,000 IU) as a population safety threshold for adults; this is not a treatment target. Use the lowest effective amount to reach the agreed range, then maintain.
• Co-factors: magnesium status can influence the vitamin D pathway; diet quality remains relevant.

The key is individualisation: start from the measured value, select a sensible regimen, and review the result. For those with malabsorption, clinical supervision is recommended.

Where broader micronutrient support is being considered alongside cholecalciferol, product choice should reflect the role in the pathway, quality, and dose transparency. Examples include magnesium for enzymatic support and zinc where diet is limited.

Bridge to products: When status is low, vitamin D remains the primary correction. Where broader nutritional support is justified, consider magnesium citrate, zinc, or omega‑3 capsules as complementary measures based on diet and clinical context.

Diet, sunlight, and fortification: what realistically helps

Three levers influence status: sunlight exposure, diet (including fortified foods), and supplements. In much of Europe, winter UVB is insufficient for significant skin synthesis, so non-sun sources become important.

• Sunlight: brief, regular exposure of face/forearms in spring, summer boosts synthesis; sun safety takes precedence.
• Foods: oily fish (e.g., salmon, mackerel), egg yolks, and liver contain vitamin D; mushrooms exposed to UV provide ergocalciferol (D₂).
• Fortification: some EU countries enrich milk, spreads, or cereals; policy varies, so labels matter.
• Supplements: practical where diet and sunlight cannot meet needs or deficiency is confirmed.

Realistically, diet and fortification often maintain but rarely correct a marked deficiency. They are still valuable in maintenance once target status is reached.

Chronic disease evidence: benefits are clearest when deficiency is present

Large trials and meta-analyses show that the most consistent benefits of vitamin D supplementation occur when baseline 25(OH)D is low. For bone outcomes, fracture reduction evidence is strongest when vitamin D is combined with calcium in deficient, institutionalised, or older populations (Weaver et al., 2016). For respiratory infections, protective effects are concentrated in those starting with low levels and using daily/weekly regimens rather than boluses (Martineau et al., 2017).

• Falls and function: recent clinical discussion cautions against indiscriminate high-dose boluses; steady dosing with monitoring is preferred (Hou et al., 2026).
• Respiratory infections: benefits are most evident in those deficient at baseline with regular dosing (Martineau et al., 2017).
• Broad chronic disease claims: associations exist, but causal benefits remain inconsistent outside deficiency correction.
• Principle: test, correct deficiency, and avoid assuming benefits where baseline is already adequate.

The clinical position is therefore balanced: confirm and correct deficiency for clear musculoskeletal benefit, and treat additional claims with the caution appropriate to the evidence quality.

Conclusion

Low 25(OH)D is common in Europe and matters most for bone and muscle health, with broader benefits clearest when deficiency is present. Priority actions are: arrange a 25(OH)D test if deficiency is suspected; use a steady, evidence-led cholecalciferol regimen and retest after 8-12 weeks; keep sun safety paramount and use dietary sources and fortification where available for maintenance. Practical steps include planning brief, regular daylight in spring, summer, choosing oily fish and fortified foods where suitable, and setting a maintenance dose once target status is reached. Alongside vitamin D, supportive nutrients such as magnesium and zinc can complement the plan where diet is limited, with high-quality omega‑3 supporting health.

Frequently asked questions

Is 25(OH)D the same as the active hormone?

No. 25(OH)D is the circulating status marker. The active hormone is 1,25-dihydroxyvitamin D, which is not used to assess vitamin D stores and can be normal or high in deficiency.

What is the difference between nmol/L and ng/mL?

They are two unit systems for 25(OH)D. Multiply ng/mL by 2.5 to convert to nmol/L (e.g., 20 ng/mL equals 50 nmol/L). Use one system consistently when applying thresholds.

How soon can levels improve after starting supplementation?

With steady daily or weekly cholecalciferol, a first review at 8-12 weeks is typical. The rise depends on baseline level, body weight, dose, and absorption. Retesting confirms whether the plan is working.

Do high-dose boluses work better?

Not necessarily. Evidence and clinical commentary warn against indiscriminate high-dose boluses, particularly in older adults where fall risk may increase. Steady, monitored dosing is preferred (Hou et al., 2026).

Can food alone correct deficiency?

Diet supports maintenance but rarely corrects marked deficiency in European settings. Oily fish, eggs, and fortified foods help, yet testing and appropriately dosed supplements are usually required for correction.

Is there a universal target level?

Thresholds differ by authority and purpose. The UK SACN emphasises <25 nmol/L as a bone-risk threshold, while many clinicians use <50 nmol/L as deficiency. Choose a definition and apply it consistently in context.

Do magnesium or zinc replace vitamin D?

No. Vitamin D is the primary correction for low 25(OH)D. Magnesium and zinc support wider metabolic processes and may complement a plan where diet is limited, but they do not substitute for cholecalciferol in deficiency.

Who should discuss testing and dosing with a clinician?

People with malabsorption, liver or kidney disease, those on interacting medications, pregnant or breastfeeding women, infants, older adults with falls or fractures, and anyone considering high-dose regimens should seek personalised advice.

Sources:

Cashman, K.D. Et al. (2016). Vitamin D deficiency in Europe: pandemic? American Journal of Clinical Nutrition, 103(4):1033-1044.

Hilger, J. Et al. (2014). A systematic review of vitamin D status in populations worldwide. Anthropologischer Anzeiger, 71(1-2):11-32.

Holick, M.F. Et al. (2011). Evaluation, treatment, and prevention of vitamin D deficiency: clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 96(7):1911-1930.

Hou, L. Et al. (2026). High-Dose Vitamin D Supplementation for Fall Prevention: Clinical Nuances and Safety Considerations. Journal of the American Geriatrics Society.

Martineau, A.R. Et al. (2017). Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of individual participant data. BMJ, 356:i6583.

SACN (2016). Vitamin D and Health. Scientific Advisory Committee on Nutrition, UK Government.

Spiro, A. & Buttriss, J.L. (2014). Vitamin D: An overview of vitamin D status and intake in Europe. Proceedings of the Nutrition Society, 73(2):1-10.

Weaver, C.M. Et al. (2016). Calcium plus vitamin D supplementation and risk of fractures: meta-analysis. Annals of Internal Medicine, 165(12):867-876.